China’s NMPA granted clinical trial clearance for CSPC Pharmaceutical Group’s JMT‑206, a candidate for weight management in people with obesity or overweight plus comorbidity. CSPC will start first‑in‑human studies in China to evaluate safety and efficacy of the program. The approval to enter the clinic places JMT‑206 among a new wave of obesity therapeutics moving rapidly into human testing in Asia, where regulatory timelines and market dynamics differ from Western jurisdictions. The clearance signals continued global competition in GLP‑1 and next‑generation weight‑management drug development.